rifamycin

rifamycin /rif·a·my·cin/ (rif″ah-mi´sin) any of a family of antibiotics biosynthesized by a strain of Streptomyces mediterranei, effective against a broad spectrum of bacteria, including gram-positive cocci, some gram-negative bacilli, and Mycobacterium tuberculosis and certain other mycobacteria; used for the treatment of tuberculosis and the prophylaxis of meningococcal infections.

---

rif·a·my·cin (rf-msn)

n.

Any of a group of antibiotics originally isolated from a strain of the soil microorganism Streptomyces mediterranei, used in the treatment of leprosy, tuberculosis, and other bacterial diseases.

---

rifamycin

[rif′ah-mi′sin]

any of a family of antibiotics biosynthesized from a strain of Streptomyces mediterranei, effective against a broad spectrum of bacteria. The five components are designated A, B, C, D, and E; rifamycins O, S, and SV are derivatives of the B component, and AG and X are derivatives of the O component. It is used for the initial treatment and retreatment of pulmonary tuberculosis and for prevention of meningococcal infections in close contacts of patients with Neisseria meningitidis infections.

---

rifamycin [rif″ah-mi´sin]

any of a family of antibiotics biosynthesized by a strain of Streptomyces mediterranei, effective against a broad spectrum of bacteria. The five components are designated A, B, C, D, and E; rifamycins O, S, and SV are derivatives of the B component, and AG and X are derivatives of the O component. Used for the initial treatment and retreatment of pulmonary tuberculosis and for prevention of meningoccal infections in close contacts of patients with Neisseria meningitidis infections.

---

rifamycin

a family of antibiotics produced in cultures of Streptomyces mediterranei. Effective against gram-positive cocci and gram-negative bacilli and mycobacteria including Mycobacterium tuberculosis.